Published • loading... • Updated
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
The 5-week trial will test whether two DehydraTECH semaglutide formulations can match Wegovy tablets on safety, tolerability and pharmacokinetic performance.
Summary by Rutland Herald
3 Articles
3 Articles
Rutland Herald+2 Reposted by 2 other sources
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7)…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
